BACKGROUND: Acute lymphoblastic leukemia (ALL) and brain tumor (BT) survivors are at risk for post-treatment IQ declines. The extent to which lower scores represent global cognitive decline versus domain-specific impairment remains unclear. This study examined discrepancies between processing speed and estimated IQ (EIQ) scores and identified clinical characteristics associated with score discrepancies in a sample of pediatric cancer survivors. PROCEDURE: Survivors (50 ALL, 50 BT) ages 12-17 years completed cognitive testing. The Wechsler Abbreviated Scale of Intelligence provided an untimed measure of general reasoning ability (EIQ). The age-appropriate Wechsler Intelligence Scale provided a Processing Speed Index (PSI) score. Scores were examined and compared. RESULTS: Survivors' PSI scores were lower than their EIQ scores (BT t(45) =6.3, p<0.001; ALL t(49) =6.9, p<0.001). For BT survivors, lower PSI scores were associated with history of craniospinal irradiation, t(44) =3.3, p<0.01. For ALL survivors, lower PSI scores were associated with male gender, grade retention, and time since diagnosis, F(3, 46) =10.1, p<0.001. Clinically significant EIQ-PSI score discrepancies were identified in 41.3% of BT and 14.0% of ALL survivors. CONCLUSIONS: Many pediatric BT and ALL survivors exhibit slower processing speed than expected for age, whereas general reasoning ability remains largely intact. Risk factors associated with larger EIQ-PSI discrepancies include the following: BT diagnosis, craniospinal irradiation (BT only), male gender, and younger age at diagnosis (ALL only). Grade retention was frequent and associated with lower EIQ scores (both groups) and PSI scores (ALL only). Describing post-treatment cognitive declines using global measures of intellectual ability may underestimate dysfunction or fail to isolate specific underlying deficits contributing to impairment.
BACKGROUND:Acute lymphoblastic leukemia (ALL) and brain tumor (BT) survivors are at risk for post-treatment IQ declines. The extent to which lower scores represent global cognitive decline versus domain-specific impairment remains unclear. This study examined discrepancies between processing speed and estimated IQ (EIQ) scores and identified clinical characteristics associated with score discrepancies in a sample of pediatric cancer survivors. PROCEDURE: Survivors (50 ALL, 50 BT) ages 12-17 years completed cognitive testing. The Wechsler Abbreviated Scale of Intelligence provided an untimed measure of general reasoning ability (EIQ). The age-appropriate Wechsler Intelligence Scale provided a Processing Speed Index (PSI) score. Scores were examined and compared. RESULTS: Survivors' PSI scores were lower than their EIQ scores (BT t(45) =6.3, p<0.001; ALL t(49) =6.9, p<0.001). For BT survivors, lower PSI scores were associated with history of craniospinal irradiation, t(44) =3.3, p<0.01. For ALL survivors, lower PSI scores were associated with male gender, grade retention, and time since diagnosis, F(3, 46) =10.1, p<0.001. Clinically significant EIQ-PSI score discrepancies were identified in 41.3% of BT and 14.0% of ALL survivors. CONCLUSIONS: Many pediatric BT and ALL survivors exhibit slower processing speed than expected for age, whereas general reasoning ability remains largely intact. Risk factors associated with larger EIQ-PSI discrepancies include the following: BT diagnosis, craniospinal irradiation (BT only), male gender, and younger age at diagnosis (ALL only). Grade retention was frequent and associated with lower EIQ scores (both groups) and PSI scores (ALL only). Describing post-treatment cognitive declines using global measures of intellectual ability may underestimate dysfunction or fail to isolate specific underlying deficits contributing to impairment.
Authors: Lisa S Kahalley; Stephanie J Wilson; Vida L Tyc; Heather M Conklin; Melissa M Hudson; Shengjie Wu; Xiaoping Xiong; Heather H Stancel; Pamela S Hinds Journal: Psychooncology Date: 2012-01-25 Impact factor: 3.894
Authors: S L Palmer; O Goloubeva; W E Reddick; J O Glass; A Gajjar; L Kun; T E Merchant; R K Mulhern Journal: J Clin Oncol Date: 2001-04-15 Impact factor: 44.544
Authors: R K Mulhern; S L Palmer; W E Reddick; J O Glass; L E Kun; J Taylor; J Langston; A Gajjar Journal: J Clin Oncol Date: 2001-01-15 Impact factor: 44.544
Authors: R K Mulhern; W E Reddick; S L Palmer; J O Glass; T D Elkin; L E Kun; J Taylor; J Langston; A Gajjar Journal: Ann Neurol Date: 1999-12 Impact factor: 10.422
Authors: Wilburn E Reddick; Holly A White; John O Glass; Gregory C Wheeler; Stephen J Thompson; Amar Gajjar; Laurie Leigh; Raymond K Mulhern Journal: Cancer Date: 2003-05-15 Impact factor: 6.860
Authors: Sarah C Carpentieri; Deborah P Waber; Scott L Pomeroy; R Michael Scott; Liliana C Goumnerova; Mark W Kieran; Amy L Billett; Nancy J Tarbell Journal: Neurosurgery Date: 2003-06 Impact factor: 4.654
Authors: Roger J Packer; James G Gurney; Judy A Punyko; Sarah S Donaldson; Peter D Inskip; Marilyn Stovall; Yutaka Yasui; Ann C Mertens; Charles A Sklar; H Stacy Nicholson; Lonnie K Zeltzer; Joseph P Neglia; Leslie L Robison Journal: J Clin Oncol Date: 2003-09-01 Impact factor: 50.717
Authors: Kimberly P Raghubar; Jessica Orobio; M Douglas Ris; Andrew M Heitzer; Alexandra Roth; Austin L Brown; M Fatih Okcu; Murali Chintagumpala; David R Grosshans; Arnold C Paulino; Anita Mahajan; Lisa S Kahalley Journal: Pediatr Blood Cancer Date: 2019-05-27 Impact factor: 3.167
Authors: Amanda L Winter; Heather M Conklin; Vida L Tyc; Heather Stancel; Pamela S Hinds; Melissa M Hudson; Lisa S Kahalley Journal: J Clin Exp Neuropsychol Date: 2014-08-15 Impact factor: 2.475
Authors: Lisa M Jacola; Jason M Ashford; Wilburn E Reddick; John O Glass; Robert J Ogg; Thomas E Merchant; Heather M Conklin Journal: J Neurooncol Date: 2014-05-22 Impact factor: 4.130
Authors: Lisa S Kahalley; Rachel Peterson; M Douglas Ris; Laura Janzen; M Fatih Okcu; David R Grosshans; Vijay Ramaswamy; Arnold C Paulino; David Hodgson; Anita Mahajan; Derek S Tsang; Normand Laperriere; William E Whitehead; Robert C Dauser; Michael D Taylor; Heather M Conklin; Murali Chintagumpala; Eric Bouffet; Donald Mabbott Journal: J Clin Oncol Date: 2019-11-27 Impact factor: 44.544
Authors: Shelli R Kesler; Meike Gugel; Mika Pritchard-Berman; Clement Lee; Emily Kutner; S M Hadi Hosseini; Gary Dahl; Norman Lacayo Journal: Pediatr Blood Cancer Date: 2014-03-12 Impact factor: 3.167
Authors: Joseph Scafidi; Jonathan Ritter; Brooke M Talbot; Jorge Edwards; Li-Jin Chew; Vittorio Gallo Journal: Cancer Res Date: 2018-03-20 Impact factor: 12.701